Investigational drug · Phase 3
DZP
Also called: CDP7657, Dapirolizumab pegol
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "DZP"
First trial start
2021
Jul 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DZP", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "DZP" as an intervention, largest first.
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusPivotal-lookingEnrolling by invitation
NCT04976322 · 760 participants (planned) · Start Jul 27, 2021 · Primary completion Aug 7, 2030
Drug: Dapirolizumab pegol · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Avondale, Arizona; Glendale, Arizona · 123 sites in all
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPivotal-lookingRecruiting
NCT06617325 · 450 participants (planned) · Start Nov 21, 2024 · Primary completion May 31, 2028
Drug: DZP · For: Systemic Lupus Erythematosus
Sites: Avondale, Arizona; Chandler, Arizona; Gilbert, Arizona · 245 sites in all
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPivotal-lookingCompleted
NCT04294667 · 321 participants · Start Aug 12, 2020 · Primary completion May 22, 2024
Drug: DZP · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 177 sites in all
- A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus ErythematosusPivotal-lookingCompleted
NCT02804763 · 182 participants · Start Jun 2, 2016 · Primary completion May 31, 2018
Drug: Placebo; Dapirolizumab pegol (DZP) · For: Systemic Lupus Erythematosus (SLE)
Sites: Birmingham, Alabama; El Cajon, California; Huntington Beach, California · 71 sites in all
BiogenBiogen (BIIB)
NCT04571424 · 33 participants · Start Oct 14, 2020 · Primary completion Apr 8, 2021
Drug: BIIB133 (Dapirolizumab pegol); Placebo · For: Healthy Volunteers
Sites: Anaheim, California
NCT07934472 · 25 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 31, 2028
Drug: Dapirolizumab pegol (DZP) · For: Systemic Lupus Erythematosus
Newest research
PubMed records naming it or its code names, newest first.
- Short-term exposure to diazepam during zebrafish embryogenesis induces intergenerational neurobehavioral disruption later in life.
Chen R, Jiang Y, Ding Z, et al. · Comp Biochem Physiol C Toxicol Pharmacol 2027
- UPLC-ESI-QToF-MS/MS profiling and anxiolytic-like effects of Simira paraensis (Baill.) Steyerm bark.
Martins LRJ, Paracampo NENP, Ribeiro PRV, et al. · J Pharm Biomed Anal 2026
- Update on biologics in SLE.
Delai M, Kyttaris VC · Curr Opin Rheumatol 2026
- [Systemic lupus erythematosus: new treatment targets and agents].
Korsten P · Dtsch Med Wochenschr 2026
- Sedative Potential of L (+)-Tartaric Acid: Behavioral Evidence With In Silico Insights Into Possible GABAergic Interaction.
Bithi SA, Chakrabarty A, Akter K, et al. · Brain Behav 2026
- Sub-chronic exposure to diazepam induces hepatic metabolism dysfunction associated with oxidative stress in zebrafish (Danio rerio).
Huang Y, Xu T, Luo T, et al. · Food Chem Toxicol 2026
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from UCB.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.